US 11,918,640 B2
Methods of preparing anti-human papillomavirus antigen T cells
Christian S. Hinrichs, Bethesda, MD (US); and Steven A. Rosenberg, Potomac, MD (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Jun. 13, 2022, as Appl. No. 17/838,662.
Application 17/838,662 is a continuation of application No. 17/372,927, filed on Jul. 12, 2021, granted, now 11,376,318.
Application 17/372,927 is a continuation of application No. 17/113,570, filed on Dec. 7, 2020, granted, now 11,077,182, issued on Aug. 3, 2021.
Application 17/113,570 is a continuation of application No. 16/218,658, filed on Dec. 13, 2018, abandoned.
Application 16/218,658 is a continuation of application No. 14/905,138, abandoned, previously published as PCT/US2014/046478, filed on Jul. 14, 2014.
Claims priority of provisional application 61/846,161, filed on Jul. 15, 2013.
Prior Publication US 2023/0139588 A1, May 4, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/00 (2006.01); A61K 35/17 (2015.01); A61K 39/12 (2006.01); C12N 5/0783 (2010.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 35/17 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C12N 7/00 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/572 (2013.01); A61K 2039/585 (2013.01); C12N 2501/2302 (2013.01); C12N 2502/30 (2013.01); C12N 2710/20011 (2013.01)] 20 Claims
 
1. A population of 1.2×1010 to 4.3×1010 HPV-specific T-cells produced by a method comprising:
(a) dividing an HPV-positive tumor sample obtained from a patient into multiple fragments;
(b) culturing the multiple fragments in the presence of at least one cytokine;
(c) obtaining T-cells from the cultured fragments; and
(d) expanding the number of T-cells to produce an expanded population of HPV-specific T-cells using:
one or both of (i) irradiated allogenic feeder cells and (ii) irradiated autologous feeder cells; and
one or both of (iii) OKT3 antibody and (iv) interleukin-2 (IL-2), wherein the T-cells have not been depleted of CD4+ cells.